noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Merck & Co. Inc.

Statement of Changes in Beneficial Ownership (Form 4)
Merck & Co. Inc.

Statement of Changes in Beneficial Ownership (Form 4)
Metro Regional Transit Authority

Transit Workers Union Local 1 Votes for Intent to Strike—Talks Continue

Healthcare

Precision BioSciences Inc.

07/01/2026 | Press release | Distributed by Public on 07/01/2026 05:17

Regulation FD Disclosure (Form 8-K)

Item 7.01 Regulation FD Disclosure.

Precision BioSciences, Inc. (the "Company") has updated its corporate deck, which is available in the "Investors" portion of the Company's website at https://investor.precisionbiosciences.com.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events

In its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The Company is targeting year-end 2026 for the next program update.

Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026.

Precision BioSciences Inc. published this content on July 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 01, 2026 at 11:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]